Celltrion Herzuma biosimilar is selling well in EuropeAn affiliate of biopharmaceutical firm Celltrion said Friday that the European market share of its breast cancer biosimilar Herzuma continued to gain ground in the first quarter of the year.
Celltrion Healthcare said Herzuma’s market share rose to 13 percent in the January-March period from 10 percent three months earlier.
The company launched the breast cancer biosimilar in seven European countries in the second quarter of last year.
The market share was 6 percent in the third quarter of that year.
Celltrion Healthcare cited data from market researcher IQVIA.
Herzuma was approved for the treatment of people diagnosed with early-stage breast cancer, metastatic breast cancer and metastatic gastric cancer. It is based on the blockbuster pill Herceptin, also known as Trastuzumab, developed by Roche.
Herzuma is Celltrion’s third biosimilar launched in Europe. The two others are Truxima, the first biosimilar monoclonal antibody for the treatment of cancer, and Remsima, the first biosimilar monoclonal antibody.
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)